Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly Share-based Compensation came in at $2.6 million in Q1 2026, up 720.19% year-on-year from $317000.0 in Q1 2025, and up 2923.26% on a QoQ basis from $86000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Share-based Compensation data on file, last reported at $2.6 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 720.19% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 68.36% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 20.0% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.6 million, up from $86000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for VVOS reached as high as $7.5 million in Q2 2024 and fell as low as -$913000.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $986647.1 across 5 years, with a median of $317000.0 in 2025.
- Across the five-year window, Share-based Compensation slumped 217.81% in 2023 and jumped 1775.0% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $775000.0 in 2022, then slumped by 217.81% to -$913000.0 in 2023, then jumped by 110.95% to $100000.0 in 2024, then dropped by 14.0% to $86000.0 in 2025, then jumped by 2923.26% to $2.6 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $2.6 million in Q1 2026, $86000.0 in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.60 Mn |
| Dec 31, 2025 | 86,000.00 |
| Dec 31, 2025 | 86,000.00 |
| Sep 30, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 7.50 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 293,000.00 |
| Mar 31, 2024 | 293,000.00 |
| Dec 31, 2023 | -913,000.00 |
| Dec 31, 2023 | -913,000.00 |